万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VNDA 万达生物制药

盘后交易 02-26 18:57:41 EST

8.60

+0.32

+3.86%

盘后8.64

+0.04+0.47%

18:51 EST

最高8.63	最低8.13	成交量229.57万
今开8.28	昨收8.28	日振幅5.98%
总市值5.08亿	流通市值4.26亿	总股本5,910万
成交额1,928万	换手率4.64%	流通股本4,948万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VNDA","market":"US","secType":"STK","nameCN":"万达生物制药","latestPrice":8.6,"timestamp":1772139600000,"preClose":8.28,"halted":0,"volume":2295747,"hourTrading":{"tag":"盘后","latestPrice":8.6407,"preClose":8.6,"latestTime":"18:51 EST","volume":82404,"amount":709836.873228,"timestamp":1772149893812,"change":0.0407,"changeRate":0.004733,"amplitude":0.023256},"delay":0,"changeRate":0.03864734299516912,"floatShares":49483146,"shares":59096630,"eps":-3.741276,"marketStatus":"盘后交易","change":0.32,"latestTime":"02-26 18:57:41 EST","open":8.28,"high":8.625,"low":8.13,"amount":19277787.018978,"amplitude":0.059783,"askPrice":8.69,"askSize":100,"bidPrice":8.48,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.741276,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772154000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1144814400000,"exchange":"NASDAQ","adjPreClose":8.28,"preHourTrading":{"tag":"盘前","latestPrice":8.28,"preClose":8.28,"latestTime":"09:29 EST","volume":29894,"amount":246733.492075,"timestamp":1772116199999,"change":0,"changeRate":0,"amplitude":0.031087},"postHourTrading":{"tag":"盘后","latestPrice":8.6407,"preClose":8.6,"latestTime":"18:51 EST","volume":82404,"amount":709836.873228,"timestamp":1772149893812,"change":0.0407,"changeRate":0.004733,"amplitude":0.023256},"volumeRatio":0.171329,"impliedVol":0.7474,"impliedVolPercentile":0.6733},"requestUrl":"/m/hq/s/VNDA","defaultTab":"news","newsList":[{"id":"1138725313","title":"万达生物制药盘前股价上涨2.3%，FDA受理其罕见皮肤病药物审查申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1138725313","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138725313?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:39","pubTimestamp":1772026751,"startTime":"0","endTime":"0","summary":"万达生物制药股价在盘前交易中录得2.3%的上涨，此前美国食品药品监督管理局已正式受理该公司针对罕见皮肤病药物的审查申请。这一进展标志着该药物在监管审批流程中迈出了关键一步，为后续可能的市场准入奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1130498462","title":"万达生物制药宣布美国FDA受理imsidolimab治疗泛发性脓疱型银屑病的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1130498462","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130498462?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:41","pubTimestamp":1772023308,"startTime":"0","endTime":"0","summary":"万达生物制药公司宣布，美国食品药品监督管理局已正式受理其候选药物imsidolimab用于治疗泛发性脓疱型银屑病的生物制品许可申请。\nFDA已为该申请设定了目标审评日期为2026年12月12日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1177212007","title":"万达生物制药宣布美国FDA受理Imsidolimab治疗泛发性脓疱型银屑病的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1177212007","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177212007?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:30","pubTimestamp":1772022603,"startTime":"0","endTime":"0","summary":"万达生物制药近日宣布，其针对泛发性脓疱型银屑病治疗的生物制剂Imsidolimab的生物制品许可申请，已获得美国食品药品监督管理局的正式受理。这一进展标志着该药物向获批上市迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"1189163157","title":"万达生物制药更新Bysanti安全警告：老年痴呆相关精神病患者死亡率上升","url":"https://stock-news.laohu8.com/highlight/detail?id=1189163157","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189163157?lang=zh_cn&edition=full","pubTime":"2026-02-21 07:02","pubTimestamp":1771628539,"startTime":"0","endTime":"0","summary":"万达生物制药公司近日对其药物Bysanti的使用说明进行了重要更新，新增了一项安全警告。该警告指出，在患有痴呆相关精神病的老年患者群体中，使用Bysanti可能导致死亡率增加。\n这一更新是基于最新的临床数据和安全性评估结果。公司强调，医疗专业人员在为这类特定患者群体处方Bysanti时，需仔细权衡其获益与潜在风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1107914472","title":"万达生物制药宣布Bysanti™（米沙哌隆）获FDA批准用于治疗双相I型障碍和精神分裂症——新化学实体开启精神科创新新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107914472","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107914472?lang=zh_cn&edition=full","pubTime":"2026-02-21 07:00","pubTimestamp":1771628411,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，其创新药物Bysanti™（米沙哌隆）已获得美国食品药品监督管理局批准，用于治疗双相I型障碍与精神分裂症。作为全新化学实体，该药物的获批标志着精神疾病治疗领域迎来重大突破，为精神病学创新开辟了全新视野。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1172660268","title":"万达生物制药公布年度营收指引：现有商业化产品收入预计达2.3亿至2.6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172660268","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172660268?lang=zh_cn&edition=full","pubTime":"2026-02-12 05:03","pubTimestamp":1770843790,"startTime":"0","endTime":"0","summary":"万达生物制药近日发布了针对当前已商业化产品的年度财务展望，公司预计其全年营收将落在2.3亿美元至2.6亿美元的区间内。这一指引反映了公司对其核心产品市场表现的信心与预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1194839696","title":"美国FDA拒绝时差症药物申请，万达生物制药盘前股价重挫近12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194839696","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194839696?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:38","pubTimestamp":1767875892,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）正式否决了万达生物制药针对时差症治疗药物的上市申请，这一监管挫折直接冲击了市场信心。\n受此消息影响，万达生物制药股价在盘前交易时段应声下挫，跌幅一度接近12%，反映出投资者对公司短期前景的担忧急剧升温。\n此次FDA的拒绝决定意味着该药物在获批道路上遭遇重大障碍，公司可能需要补充更多临床数据或调整申请策略，从而推迟了潜在商业化时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1185252065","title":"万达生物制药宣布收到美国食品药品监督管理局关于Hetlioz®时差障碍补充新药申请的决定函","url":"https://stock-news.laohu8.com/highlight/detail?id=1185252065","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185252065?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:10","pubTimestamp":1767874255,"startTime":"0","endTime":"0","summary":"万达生物制药今日宣布，已正式收到美国食品药品监督管理局（FDA）针对其Hetlioz®药物治疗时差障碍的补充新药申请（sNDA）所发出的决定函。\n此次决定函的接收标志着Hetlioz®在拓展适应症方面迈出了关键一步。Hetlioz®是该公司的一款核心产品，此次补充申请旨在将其应用范围延伸至时差障碍的治疗领域。\n公司表示，将仔细评估FDA决定函中的具体内容，并据此确定下一步的研发与申报策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2595670884","title":"美股异动 | 止吐新药Nereus获FDA批准 万达生物制药(VNDA.US)涨超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670884","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670884?lang=zh_cn&edition=full","pubTime":"2025-12-31 23:30","pubTimestamp":1767195022,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，万达生物制药股价走高，截至发稿，该股涨超32%，报9.33美元。消息面上，公司表示，其新药Nereus已获得美国食品药品监督管理局批准，该药物可用于预防由运动引发的呕吐。公司称，FDA的批准决定基于三项临床研究结果。数据显示，Nereus在降低呕吐事件方面取得“显著减少”的效果，同时在短期、急性使用场景下展现出“良好的安全性特征”。Vanda表示，计划在未来几个月内正式推出Nereus。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1156607691","title":"万达生物制药：预防运动诱发性呕吐的药物已获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1156607691","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156607691?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:46","pubTimestamp":1767192391,"startTime":"0","endTime":"0","summary":"将在未来几个月内推出这款药物。","market":"us","thumbnail":"https://static.tigerbbs.com/f1f500cd9736f933a7db617c54d95bf2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f1f500cd9736f933a7db617c54d95bf2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e2d2cba8f51f8d5dd55fcc10b72c287c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"万达生物制药：预防运动诱发性呕吐的药物已获FDA批准","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA"],"gpt_icon":0},{"id":"1163050698","title":"盘前｜VNDA暴涨20%，特斯拉快速拉升，英伟达、台积电曝重磅消息","url":"https://stock-news.laohu8.com/highlight/detail?id=1163050698","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163050698?lang=zh_cn&edition=full","pubTime":"2025-12-31 20:37","pubTimestamp":1767184642,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前时段小幅走低。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","TSLA","TSM"],"gpt_icon":1},{"id":"1141618656","title":"盘前异动｜万达生物制药暴涨22%，贵金属概念普跌，小鹏汽车跌超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141618656","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141618656?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:17","pubTimestamp":1767172637,"startTime":"0","endTime":"0","summary":"$万达生物制药$ 盘前暴涨超22%，市场消息称FDA批准公司旗下药物用于预防运动引起的呕吐。现货白银日内跌超6%，现货黄金一度跌超1%，相关概念盘前普跌。主要芯片股盘前涨跌不一。$百度$ 盘前涨超1%。百度智能云公布的数据显示，AI眼镜、学习机、康养设备及情感陪伴类硬件等新型交互产品出货量增速远超传统消费电子产品，部分细分领域年增长率突破30%。截至发稿，小鹏汽车跌超4%，蔚来、理想汽车跌超3%。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e2d2cba8f51f8d5dd55fcc10b72c287c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGQ","XPEV","VNDA"],"gpt_icon":0},{"id":"1149801107","title":"消息称FDA批准万达生物制药旗下药物用于预防运动引起的呕吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1149801107","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149801107?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:12","pubTimestamp":1767172322,"startTime":"0","endTime":"0","summary":"批准公司旗下药物用于预防运动引起的呕吐。","market":"us","thumbnail":"https://static.tigerbbs.com/f1f500cd9736f933a7db617c54d95bf2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f1f500cd9736f933a7db617c54d95bf2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e2d2cba8f51f8d5dd55fcc10b72c287c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA"],"gpt_icon":0},{"id":"1123209938","title":"万达生物制药股价在盘前交易中上涨6.1% 因公司提交了Gpp药物的生物许可证申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1123209938","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123209938?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:53","pubTimestamp":1765803191,"startTime":"0","endTime":"0","summary":"万达生物制药股价在盘前交易中上涨6.1%，因公司提交了Gpp药物的生物许可证申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"1124874010","title":"万达生物制药：优先审查将确立6个月审查周期，Imsidolimab有望于2026年中期获得FDA批准用于GPP治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1124874010","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124874010?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:03","pubTimestamp":1765800198,"startTime":"0","endTime":"0","summary":"万达生物制药：优先审查将确立6个月审查周期，Imsidolimab有望于2026年中期获得FDA批准用于GPP治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139","VNDA"],"gpt_icon":0},{"id":"1127045654","title":"万达生物制药提交生物制剂许可证申请给FDA，申请用于治疗广义脓疱型银屑病的Imsidolimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1127045654","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127045654?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:02","pubTimestamp":1765800154,"startTime":"0","endTime":"0","summary":"万达生物制药提交生物制剂许可证申请给FDA，申请用于治疗广义脓疱型银屑病的Imsidolimab","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","ANAB","BK4139"],"gpt_icon":0},{"id":"1164286102","title":"万达生物制药股价在盘前交易中上涨7%，因其在防止GLP-1诱发的恶心和呕吐方面报告了积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164286102","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164286102?lang=zh_cn&edition=full","pubTime":"2025-11-18 17:18","pubTimestamp":1763457495,"startTime":"0","endTime":"0","summary":"万达生物制药股价在盘前交易中上涨7%，因其在防止GLP-1诱发的恶心和呕吐方面报告了积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"1108858715","title":"万达生物制药公布Tradipitant在预防GLP-1引起的恶心和呕吐方面的积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1108858715","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108858715?lang=zh_cn&edition=full","pubTime":"2025-11-18 07:38","pubTimestamp":1763422689,"startTime":"0","endTime":"0","summary":"万达生物制药公布Tradipitant在预防GLP-1引起的恶心和呕吐方面的积极成果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2580788107","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788107?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:31","pubTimestamp":1762180273,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日22时31分，Vanda Pharmaceuticals Inc.股票出现波动，股价大幅上涨5.06%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.10%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322311494ec54b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322311494ec54b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2574187552","title":"Vanda Pharmaceuticals Inc.盘中异动 下午盘急速上涨5.08%报5.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574187552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574187552?lang=zh_cn&edition=full","pubTime":"2025-10-09 01:10","pubTimestamp":1759943458,"startTime":"0","endTime":"0","summary":"北京时间2025年10月09日01时10分，Vanda Pharmaceuticals Inc.股票出现波动，股价急速上涨5.08%。截至发稿，该股报5.59美元/股，成交量31.1191万股，换手率0.53%，振幅5.27%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009011058a6b0f458&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009011058a6b0f458&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XBIOW","VNDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vandapharma.com","stockEarnings":[{"period":"1week","weight":0.3731},{"period":"1month","weight":0.0643},{"period":"3month","weight":0.5623},{"period":"6month","weight":0.7505},{"period":"1year","weight":0.8565},{"period":"ytd","weight":-0.0612}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vanda Pharmaceuticals Inc.于2002年在特拉华州注册成立。该公司是一家全球领先的生物制药公司，专注于创新疗法的开发和商业化，以解决高度未满足的医疗需求并改善患者的生活。该公司努力推进新的方法，通过负责任的创新将重要的新药推向市场。该公司致力于在药物发现、临床试验和产品的商业定位中使用支持健全科学的技术，包括遗传学和基因组学。","yearOnYearQuotes":[{"month":1,"riseRate":0.45,"avgChangeRate":-0.03173},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002611},{"month":3,"riseRate":0.421053,"avgChangeRate":-0.018829},{"month":4,"riseRate":0.421053,"avgChangeRate":-0.012671},{"month":5,"riseRate":0.473684,"avgChangeRate":0.765369},{"month":6,"riseRate":0.6,"avgChangeRate":0.048231},{"month":7,"riseRate":0.4,"avgChangeRate":-0.033343},{"month":8,"riseRate":0.45,"avgChangeRate":-0.00253},{"month":9,"riseRate":0.3,"avgChangeRate":-0.047775},{"month":10,"riseRate":0.45,"avgChangeRate":-0.012144},{"month":11,"riseRate":0.65,"avgChangeRate":0.054208},{"month":12,"riseRate":0.55,"avgChangeRate":0.052442}],"exchange":"NASDAQ","name":"万达生物制药","nameEN":"Vanda Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万达生物制药,VNDA,万达生物制药股票,万达生物制药股票老虎,万达生物制药股票老虎国际,万达生物制药行情,万达生物制药股票行情,万达生物制药股价,万达生物制药股市,万达生物制药股票价格,万达生物制药股票交易,万达生物制药股票购买,万达生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}